Repurposing GLP-1 Drugs to Improve Myocardial Reperfusion Following Acute Infarction

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Communications. https://doi.org/10.1038/s41467-026-69555-1  
Dr. Svetlana Mastitskaya  et al.

Points

A new study indicates that GLP-1 drugs may prevent “no-reflow” complications which currently affect approximately fifty percent of patients who have undergone emergency treatment for an acute heart attack.
Researchers discovered that small contractile cells known as pericytes constrict the coronary capillaries during ischemia which prevents oxygen-rich blood from reaching vital heart tissue even after the main artery clears.
The administration of GLP-1 agonists triggers the activation of ATP-sensitive potassium channels on these pericytes to induce relaxation and allow constricted blood vessels to dilate for improved myocardial blood flow.
Experimental data suggests that this cardioprotective response is part of a native brain-gut-heart signaling pathway that can be activated pharmacologically or through specific physiological triggers such as skeletal muscle ischemia.
These findings highlight a significant opportunity to repurpose existing diabetes and obesity medications to reduce the incidence of heart failure and death within one year of a major cardiac event.

Summary

This study investigated the therapeutic potential of glucagon-like peptide 1 (GLP-1) in addressing coronary “no-reflow,” a complication affecting up to 50% of patients following the successful unblocking of a coronary artery. Despite the clearance of primary occlusions, constricted pericytes often maintain capillary blockages, leading to reduced left ventricular ejection fraction and increased infarct size. Researchers identified that these small contractile cells constrict coronary capillaries at the onset of ischemia, preventing oxygen-rich blood from reaching cardiac tissue even after emergency intervention.

Utilizing animal models, the research team demonstrated that GLP-1 improves myocardial perfusion by activating ATP-sensitive potassium ($K_{ATP}$) channels on pericytes. The activation of these channels induces pericyte relaxation and subsequent capillary dilation, effectively reversing the microvascular resistance that characterizes the no-reflow phenomenon. This mechanism is part of a complex brain-gut-heart pathway where skeletal muscle ischemia can evoke vagally-mediated GLP-1 release from the gut to provide endogenous cardioprotection.

The findings suggest that repurposing existing GLP-1 agonists—currently utilized for type 2 diabetes and obesity—could significantly reduce post-infarct morbidity. By preventing the narrowing of tiny blood vessels that leads to heart failure or death within one year of a heart attack, these pharmacological interventions offer a targeted strategy to stabilize the microvasculature. While specific hazard ratios and confidence intervals were not explicitly detailed in the provided text, the physiological impact on the 50% of patients at risk for no-reflow highlights a high-priority clinical application.

Link to the article: https://www.nature.com/articles/s41467-026-69555-1

References

Mastitskaya, S., de Freitas, F. S. S., Evans, L. E., & Attwell, D. (2026). GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection. Nature Communications. https://doi.org/10.1038/s41467-026-69555-1